Overview

Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the how well linaclotide works in treating patients with stages 0-3 colorectal cancer. Linaclotide is a very small protein that binds to receptors on intestinal cells and makes them secrete water and salt.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborator:
United States Department of Defense
Treatments:
Linaclotide